Hoth Therapeutics Inc., a biopharmaceutical company specializing in treatments for rare and inflammatory diseases, has announced positive preclinical safety data for its investigational oncology candidate, HT-KIT. The study results, which have already been presented, demonstrated a dose-dependent increase in liver mass without any observed toxicity or adverse effects on other organs such as the kidney, spleen, and thymus. The findings support the safety profile of HT-KIT, with no visible lesions or gross pathology noted in treated animals. Hoth Therapeutics plans to proceed with GLP toxicology studies and aims to submit an Investigational New Drug $(IND.AU)$ application, marking a key step toward future clinical trials.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。